BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28977902)

  • 1. ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways.
    Ni X; Zhang X; Hu CH; Langridge T; Tarapore RS; Allen JE; Oster W; Duvic M
    Oncotarget; 2017 Sep; 8(37):61761-61776. PubMed ID: 28977902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ONC201/TIC10 plus TLY012 anti-cancer effects via apoptosis inhibitor downregulation, stimulation of integrated stress response and death receptor DR5 in gastric adenocarcinoma.
    Parker CS; Zhou L; Prabhu VV; Lee S; Miner TJ; Ross EA; El-Deiry WS
    Am J Cancer Res; 2023; 13(12):6290-6312. PubMed ID: 38187068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
    Prabhu VV; Talekar MK; Lulla AR; Kline CLB; Zhou L; Hall J; Van den Heuvel APJ; Dicker DT; Babar J; Grupp SA; Garnett MJ; McDermott U; Benes CH; Pu JJ; Claxton DF; Khan N; Oster W; Allen JE; El-Deiry WS
    Cell Cycle; 2018; 17(4):468-478. PubMed ID: 29157092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
    Talekar MK; Allen JE; Dicker DT; El-Deiry WS
    Cell Cycle; 2015 Aug; 14(15):2422-8. PubMed ID: 26030065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
    Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
    Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine pre-treatment impairs the anti-cancer effect of integrated stress response- and TRAIL pathway-inducing ONC201, ONC206 and ONC212 imipridones in pancreatic, colorectal cancer but not DMG cells.
    Zhang Y; Tapinos N; Lulla R; El-Deiry WS
    Am J Cancer Res; 2024; 14(5):2453-2464. PubMed ID: 38859853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases.
    Kline CL; Van den Heuvel AP; Allen JE; Prabhu VV; Dicker DT; El-Deiry WS
    Sci Signal; 2016 Feb; 9(415):ra18. PubMed ID: 26884600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
    Allen JE; Krigsfeld G; Patel L; Mayes PA; Dicker DT; Wu GS; El-Deiry WS
    Mol Cancer; 2015 May; 14():99. PubMed ID: 25927855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic activity of ABT-263 and ONC201/TIC10 against solid tumor cell lines is associated with suppression of anti-apoptotic Mcl-1, BAG3, pAkt, and upregulation of pro-apoptotic Noxa and Bax cleavage during apoptosis.
    Di Cristofano FR; Fong MW; Huntington KE; Carneiro BA; Zhou L; El-Deiry WS
    Am J Cancer Res; 2023; 13(1):307-325. PubMed ID: 36777502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
    Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
    Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
    Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
    Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).
    Liguori NR; Sanchez Sevilla Uruchurtu A; Zhang L; Abbas AE; Lee YS; Zhou L; Azzoli CG; El-Deiry WS
    Am J Cancer Res; 2022; 12(2):729-743. PubMed ID: 35261798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and clinical introduction of first-in-class imipridone ONC201.
    Allen JE; Kline CL; Prabhu VV; Wagner J; Ishizawa J; Madhukar N; Lev A; Baumeister M; Zhou L; Lulla A; Stogniew M; Schalop L; Benes C; Kaufman HL; Pottorf RS; Nallaganchu BR; Olson GL; Al-Mulla F; Duvic M; Wu GS; Dicker DT; Talekar MK; Lim B; Elemento O; Oster W; Bertino J; Flaherty K; Wang ML; Borthakur G; Andreeff M; Stein M; El-Deiry WS
    Oncotarget; 2016 Nov; 7(45):74380-74392. PubMed ID: 27602582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.
    Ishizawa J; Kojima K; Chachad D; Ruvolo P; Ruvolo V; Jacamo RO; Borthakur G; Mu H; Zeng Z; Tabe Y; Allen JE; Wang Z; Ma W; Lee HC; Orlowski R; Sarbassov dos D; Lorenzi PL; Huang X; Neelapu SS; McDonnell T; Miranda RN; Wang M; Kantarjian H; Konopleva M; Davis RE; Andreeff M
    Sci Signal; 2016 Feb; 9(415):ra17. PubMed ID: 26884599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells.
    Yuan X; Kho D; Xu J; Gajan A; Wu K; Wu GS
    Oncotarget; 2017 Mar; 8(13):21626-21638. PubMed ID: 28423492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
    Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
    Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents.
    Sors A; Jean-Louis F; Bégué E; Parmentier L; Dubertret L; Dreano M; Courtois G; Bachelez H; Michel L
    Clin Cancer Res; 2008 Feb; 14(3):901-11. PubMed ID: 18245554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.
    Zhang C; Li B; Gaikwad AS; Haridas V; Xu Z; Gutterman JU; Duvic M
    J Invest Dermatol; 2008 Nov; 128(11):2728-2735. PubMed ID: 18496567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling.
    Zhang C; Li B; Zhang X; Hazarika P; Aggarwal BB; Duvic M
    J Invest Dermatol; 2010 Aug; 130(8):2110-9. PubMed ID: 20393484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study.
    Feng Y; Zhou J; Li Z; Jiang Y; Zhou Y
    PLoS One; 2016; 11(9):e0162133. PubMed ID: 27626799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.